To date, in the hopes of commercializing key biopharma products like vaccines, Canada has delivered significant dollars directly to companies. While this will certainly help bolster the industry—or at least elements of its operation—what’s further needed are investments in fundamental research in health and biomedicine.
To continue reading about the need to further fund innovation, click here for the article on The Hill Times’ website.
